Search results
Results from the WOW.Com Content Network
Modalities applied to measurement of ejection fraction is an emerging field of medical mathematics and subsequent computational applications. The first common measurement method is echocardiography, [7] [8] although cardiac magnetic resonance imaging (MRI), [8] [9] cardiac computed tomography, [8] [9] ventriculography and nuclear medicine (gated SPECT and radionuclide angiography) [8] [10 ...
In normal subjects, the left ventricular ejection fraction (LVEF) should be about 50% [9] (range, 50-80%). There should be no area of abnormal wall motion ( hypokinesis , akinesis or dyskinesis ). Abnormalities in cardiac function may be manifested as a decrease in LVEF and/or the presence of abnormalities in global and regional wall motion.
Heart failure with preserved ejection fraction (HFpEF) is a form of heart failure in which the ejection fraction – the percentage of the volume of blood ejected from the left ventricle with each heartbeat divided by the volume of blood when the left ventricle is maximally filled – is normal, defined as greater than 50%; [1] this may be measured by echocardiography or cardiac catheterization.
Heart failure is categorized by a measurement known as ejection fraction. Ejection fraction is the amount of blood that the left ventricle of your heart pumps out each time it contracts.
The function of the myocardium is also evaluated by calculating the left ventricular ejection fraction (LVEF) of the heart. This scan is done in conjunction with a cardiac stress test. The diagnostic information is generated by provoking controlled regional ischemia in the heart with variable perfusion.
Heart failure with mildly reduced ejection fraction (HFmrEF), previously called "heart failure with mid-range ejection fraction", [63] is defined by an ejection fraction of 41–49%. [ 63 ] Heart failure with preserved ejection fraction (HFpEF): Synonyms no longer recommended include "diastolic heart failure" and "heart failure with normal ...
The RALES trial [30] showed that the addition of spironolactone can improve mortality, particularly in severe cardiomyopathy (ejection fraction less than 25%.) The related medication eplerenone was shown in the EPHESUS trial [ 31 ] to have a similar effect, and it is specifically labelled for use in decompensated heart failure complicating ...
For premium support please call: 800-290-4726 more ways to reach us